NASDAQ:PODDInsulet Stock Price, Forecast & News

Insulet's stock was trading at $172.11 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PODD stock has increased by 13.4% and is now trading at $195.18. View which stocks have been most impacted by Coronavirus.

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 1 sell rating, 9 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Insulet.

Insulet is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Insulet.

Insulet will be holding an earnings conference call on Thursday, August 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Insulet Co. (NASDAQ:PODD) released its earnings results on Thursday, May, 7th. The medical instruments supplier reported ($0.03) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.02) by $0.01. The medical instruments supplier had revenue of $198 million for the quarter, compared to the consensus estimate of $189.61 million. Insulet had a return on equity of 7.66% and a net margin of 0.66%. The firm's revenue was up 23.8% compared to the same quarter last year. During the same period in the previous year, the company earned $0.07 EPS. View Insulet's earnings history.

Insulet issued an update on its second quarter 2020 After-Hours earnings guidance on Thursday, May, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $210.792-217.877 million, compared to the consensus revenue estimate of $201.99 million.

19 equities research analysts have issued twelve-month price objectives for Insulet's stock. Their forecasts range from $140.00 to $250.00. On average, they expect Insulet's stock price to reach $196.44 in the next year. This suggests a possible upside of 0.6% from the stock's current price. View analysts' price targets for Insulet.

Media coverage about PODD stock has trended positive on Thursday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Insulet earned a news impact score of 2.1 on InfoTrie's scale. They also assigned media headlines about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. View the latest news about Insulet.

Some companies that are related to Insulet include Abbott Laboratories (ABT), Medtronic (MDT), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Stryker (SYK), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Steris (STE) and ABIOMED (ABMD). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include DexCom (DXCM), NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Veeva Systems (VEEV), Adobe (ADBE), salesforce.com (CRM), Shopify (SHOP), Teladoc Health (TDOC) and Alteryx (AYX).

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Insulet's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Scout Investments Inc. (0.18%), Envestnet Asset Management Inc. (0.07%), State of Alaska Department of Revenue (0.03%), First Citizens Bank & Trust Co. (0.02%), IFM Investors Pty Ltd (0.01%) and Nelson Van Denburg & Campbell Wealth Management Group LLC (0.01%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Charles Alpuche, Corinne H Nevinny, David A Lemoine, David Colleran, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View institutional ownership trends for Insulet.

PODD stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc., James Hambro & Partners, and IFM Investors Pty Ltd. Company insiders that have sold Insulet company stock in the last year include Corinne H Nevinny, David A Lemoine, John A Fallon, Michael P Spears, and Shacey Petrovic. View insider buying and selling activity for Insulet.

PODD stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Envestnet Asset Management Inc., First Citizens Bank & Trust Co., Nelson Van Denburg & Campbell Wealth Management Group LLC, Gateway Investment Advisers LLC, Exchange Traded Concepts LLC, and IBM Retirement Fund. View insider buying and selling activity for Insulet.

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PODD stock can currently be purchased for approximately $195.18.

Insulet has a market capitalization of $12.31 billion and generates $738.20 million in revenue each year. The medical instruments supplier earns $11.60 million in net income (profit) each year or $0.19 on an earnings per share basis. Insulet employs 1,350 workers across the globe.

The official website for Insulet is www.insulet.com.

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]